UroGen Pharma URGN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.97M-0.7% | $110.75M+23.0% | $90.04M-3.1% | $92.9M-10.7% | $104.03M-39.5% | ||
| $30.31M+212% | $9.71M-73.7% | $36.99M-42.2% | $64.05M-30.3% | $91.86M+42.0% | ||
| $55.41M+67.5% | $33.08M+67.9% | $19.7M+0.3% | $19.65M+0.1% | $19.64M-3.3% | ||
| $20.92M+27.1% | $16.46M+97.4% | $8.34M+17.0% | $7.13M-6.1% | $7.59M-17.7% | ||
| $237.46M+27.7% | $186.02M+10.4% | $168.55M-14.4% | $196.87M-17.0% | $237.18M-14.1% | ||
| $616K-3.3% | $637K-8.3% | $695K+1.0% | $688K+9.7% | $627K-4.3% | ||
| $253.69M+26.6% | $200.46M+8.3% | $185.05M-11.3% | $208.72M-15.7% | $247.62M-13.3% | ||
| $35.35M+27.5% | $27.72M+5.9% | $26.17M-15.5% | $30.96M+2.1% | $30.32M+10.5% | ||
| $50.64M+9.1% | $46.42M+9.9% | $42.24M-11.2% | $47.55M+13.2% | $42M-8.6% | ||
| $189.53M+55.1% | $122.21M+0.1% | $122.11M-0.3% | $122.51M+0.3% | $122.11M+0.3% | ||
| $377.94M+23.5% | $305.93M+1.8% | $300.45M-0.5% | $302.09M+2.7% | $294.08M-0.1% | ||
| $134K+0.8% | $133K+3.9% | $128K+1.6% | $126K0.0% | $126K+9.6% | ||
| -$983.29M-2.5% | -$959.72M-2.8% | -$933.35M-3.7% | -$900.01M-5.9% | -$850.07M-5.4% | ||
| -$124.25M-17.8% | -$105.47M+8.6% | -$115.41M-23.6% | -$93.38M-101% | -$46.46M-428% | ||
| $253.69M+26.6% | $200.46M+8.3% | $185.05M-11.3% | $208.72M-15.7% | $247.62M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can UroGen Pharma cover its short-term obligations?
- Its current ratio is 4.69 — current assets exceed current liabilities.
- Where does UroGen Pharma's balance sheet data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.